These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31258693)

  • 21. MicroRNA-206 inhibits metastasis of triple-negative breast cancer by targeting transmembrane 4 L6 family member 1.
    Fan C; Liu N; Zheng D; Du J; Wang K
    Cancer Manag Res; 2019; 11():6755-6764. PubMed ID: 31413629
    [No Abstract]   [Full Text] [Related]  

  • 22. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.
    Zhao PW; Cui JX; Wang XM
    Pharmacogenomics J; 2024 Feb; 24(2):5. PubMed ID: 38378770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2.
    Zhao M; Zhang M; Tao Z; Cao J; Wang L; Hu X
    Technol Cancer Res Treat; 2020; 19():1533033820905824. PubMed ID: 32174262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
    Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
    Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147.
    Wang C; Xu C; Niu R; Hu G; Gu Z; Zhuang Z
    BMC Cancer; 2019 Jun; 19(1):577. PubMed ID: 31196010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-1297 downregulation inhibits breast cancer cell epithelial-mesenchymal transition and proliferation in a FA2H-dependent manner.
    Li H; Lian B; Liu Y; Chai D; Li J
    Oncol Lett; 2020 Dec; 20(6):277. PubMed ID: 33014155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.
    Li S; Li Q; Lü J; Zhao Q; Li D; Shen L; Wang Z; Liu J; Xie D; Cho WC; Xu S; Yu Z
    Front Genet; 2019; 10():1278. PubMed ID: 32010177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
    Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
    Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer.
    Xi Y; Li T; Xi Y; Zeng X; Miao Y; Guo R; Zhang M; Li B
    Cancer Cell Int; 2022 Sep; 22(1):271. PubMed ID: 36050724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiR-145 promotes TNF-α-induced apoptosis by facilitating the formation of RIP1-FADDcaspase-8 complex in triple-negative breast cancer.
    Zheng M; Wu Z; Wu A; Huang Z; He N; Xie X
    Tumour Biol; 2016 Jul; 37(7):8599-607. PubMed ID: 26733177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1.
    Wang JH; Wang XW; Qu D; Sun JW; Guo FX; Lu D
    Oncol Lett; 2017 Jun; 13(6):4695-4700. PubMed ID: 28588724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer.
    Zhang X; Ma G; Liu J; Zhang Y
    Oncol Lett; 2017 Oct; 14(4):4805-4811. PubMed ID: 29085483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of TNKS2.
    Jia Z; Liu Y; Gao Q; Han Y; Zhang G; Xu S; Cheng K; Zou W
    Gene; 2016 Nov; 593(1):41-47. PubMed ID: 27506313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-589 serves as a tumor suppressor microRNA through directly targeting metastasis-associated protein 2 in breast cancer.
    Chu J
    Oncol Lett; 2019 Sep; 18(3):2232-2239. PubMed ID: 31452724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer.
    Wei C; Luo Q; Sun X; Li D; Song H; Li X; Song J; Hua K; Fang L
    Int J Clin Exp Pathol; 2015; 8(7):7729-39. PubMed ID: 26339338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels.
    De Blasio A; Pratelli G; Drago-Ferrante R; Saliba C; Baldacchino S; Grech G; Tesoriere G; Scerri C; Vento R; Di Fiore R
    J Cell Physiol; 2019 Aug; 234(10):18432-18447. PubMed ID: 30912136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-429 mediates δ-tocotrienol-induced apoptosis in triple-negative breast cancer cells by targeting XIAP.
    Wang C; Ju H; Shen C; Tong Z
    Int J Clin Exp Med; 2015; 8(9):15648-56. PubMed ID: 26629059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.
    Li G; Yang M; Zuo L; Wang MX
    Oncol Lett; 2018 Jun; 15(6):9934-9940. PubMed ID: 29805690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.